DIAGNOSE EARLIER
It is possible to diagnose more cancers at early stages, when they are asymptomatic and can be cured with less aggressive treatments
AT PRESENT
We have new methods for detecting cancer. In our Early Diagnosis Unit, we want to bring these new technologies and knowledge to people.
As doctors, we feel the need to implement these advances to make them accessible to people, and also to collaborate and take part in the development of these technologies through clinical implementation and research.
WHY?
Detect earlier
There is a clear need to diagnose cancer earlier in order to achieve more cures and use less aggressive treatments.
Pending advances
Current population screening methods are necessary and recommendations should be followed, but they are far from solving the problem.
Early diagnosis
Survival rates for cancer diagnosed at an early stage are very high.
Current challenges
Currently, tumours that do not have screening methods account for 71% of cancer deaths.
Technology
For some years now, we have had the tools and technology needed to make significant progress in that direction.
WHY?
Detect earlier
There is a clear need to diagnose cancer earlier in order to achieve more cures and use less aggressive treatments.
Pending advances
Current population screening methods are necessary and recommendations should be followed, but they are far from solving the problem.
Early diagnosis
Survival rates for cancer diagnosed at an early stage are very high.
Current challenges
Currently, tumours that do not have screening methods account for 71% of cancer deaths.
Technology
For some years now, we have had the tools and technology needed to make significant progress in that direction.
HOW?
In our Early Diagnosis Unit, we carry out a comprehensive assessment of the individual and propose strategies based on scientific evidence.
HOW?
In our Early Diagnosis Unit, we carry out a comprehensive assessment of the individual and propose strategies based on scientific evidence.
Chest CT scan
Imaging examination that allows detection of lung abnormalities at very early stages.MRCP (magnetic resonance cholangiopancreatography) / endoscopic ultrasound.
Advanced techniques for studying the pancreas, liver and biliary tract.Blood liquid biopsy
Search for tumour cells or altered DNA to detect asymptomatic tumours.Urine genetic analysis
Non-invasive test to detect urological tumours earlier, through analysis of DNA methylation patterns in urine.Artificial intelligence
AI applied to genetic and protein analysis in blood.Optimisation
We optimize existing screening programs for breast, colon, prostate, and lung cancer based on the characteristics of each individual.WHO ARE WE?
Lucia Carril Ajuria
Medical Oncology Specialist from the Hospital 12 de Octubre in Madrid, specializing in genitourinary tumors. She has participated in clinical and translational research projects at Gustave Roussy Institute in Paris, in the areas of renal cancer and immunomonitoring.
She holds a PhD from the Complutense University of Madrid, graduating with highest honors (Cum Laude). She also holds a University Diploma in Clinical Oncology and a European Diploma in Clinical and Translational Cancer Research from Paris-Saclay University.
She is the first author of numerous scientific publications in journals with an impact factor and has presented numerous scientific papers at international conferences. Her work has earned her several Merit Awards from the American Society of Clinical Oncology (ASCO) and the International Kidney Cancer Symposium (IKCS). She has participated as a speaker at numerous oncology conferences, as well as in training programs and national and international scientific meetings. She has received research grants from the Spanish Society of Medical Oncology (SEOM) and Paris-Saclay University. She also participates, when requested, in the peer review of articles for international scientific journals.
Currently, she works as a medical oncologist at Saint-Pierre University Hospital in Brussels and in the Unidad de Diagnostico Precoz.
Member of SEOM, BSMO, and ESMO.
Languages: Spanish, English, and French.
Jesús Poveda Ferriols
Medical doctor specialised in Medical Oncology at the Hospital Clínico Universitario de Valencia, with a focus on breast cancer and gynaecological tumours. He holds a Master’s degree in Clinical Medicine from the Camilo José Cela University in Madrid.
He is the Principal Investigator for multiple Phase 3 clinical trials and has authored several scientific publications and presentations at international congresses as first author."
He currently works as a medical oncologist at Saint-Pierre University Hospital in Brussels and at the Early Diagnosis Unit.
Member of SEOM, BSMO and ESMO.
Languages: Spanish, English, French and Valencian.
WHERE DO WE CONSULT?
Saint-Pierre University Hospital, Brussels
Urosalud Clinic, Valencia
Online
WHERE DO WE CONSULT?
C.H.U. Saint Pierre Bruselas
Urosalud Clinic, Valencia
Online
